Epizyme Inc. (EPZM) is owned by a number of high-value investors. Its largest direct holder is Robert B. Bazemore President, Chief Executive Officer and Director with 84,994 shares. The second-largest direct holder is Shefali Agarwal Chief Medical Officer, with 35,699 shares of the company’s stock. In third place with 18,118 shares of EPZM is David M. Mott Chairman of the board.
Now turning to institutional ownership of Epizyme Inc. (EPZM), PRIMECAP Management Co. is the top holder with 11.47 million shares. The next largest fund holder of this company’s stock is Redmile Group LLC with 8.64 million shares. In the third-place spot with 7.01 million shares is The Vanguard Group, Inc..
This company’s stock price was $15.76 at the previous market close, with its latest volume reaching 1265250. Compare that to its average daily volume of 680.01K. Given the fact that this stock has 91.68M shares outstanding, its current market value is sitting at $1.44B. This publicly-traded stock’s 60-month Beta is 2.58. Its Price to Sales ratio is 49.48, its Price to Cash Flow ratio is 4.93, and its Price to Book ratio is 5.59.
EPZM stock has achieved a 5-day range of $15.00 to $16.98, with a total performance of -6.25% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $12.26 to $17.00, generating a +33.00% change during the period. In the past three months, this stock’s price has changed by +21.51%, trading in the range of $9.73 to $17.00.
In the past 5 days, shares of EPZM have made a new high 1 time. In the last month, it has made a new high 14 times, and in the past 3 months, it has made a new high 15 times.
Now let’s turn to this public company’s earnings. For the quarter ending 9/29/2019, the earnings per share (EPS) was reported at -0.4. This is a 0.13 difference compared to the consensus estimate of -0.53, amounting to an earnings surprise of 24.50%. In the previous quarter, which ended in 9/29/2019, the consensus estimate was -0.53, making for an earnings surprise of 0.00%. For the quarter ending 3/30/2019, EPS was reported at -0.39, generating a 15.20% earnings surprise.
The Net Income for the most recent full fiscal year, which ended in 12-2018, was $-123.63 million. This is compared to the prior year, where Net Income was $-134.31 million. Meanwhile, this company’s Operating Cash Flow was $-121.6 million for the year, compared to $-120.43 million in 2017. Capital Expenditures for the year were reportedly $299000.0, compared to $984000.0, and Free Cash flow was $-121.9 million compared to the prior year’s $-121.42 million.
Epizyme Inc. (EPZM) stock currently has a Financial Strength score of 7/10. This is due to a combination of factors, including a Cash to Debt ratio of 28.86, an Equity to Asset ratio of 0.88, a Debt to Equity ratio of 0.04 and a Debt to EBITDA of -0.07. The Piotroski F-Score is 3, its Altman Z-Score is 19.16 and its Beneish M-Score is -1.09.
This publicly-traded company’s Profitability and Growth score is 1/10, thanks to a combination of things: an Operating Margin of -492.91, a Net Margin of -468.53, a ROE of -50.19, and a ROC of -1740.99.
Shifting focus now to Valuation and Return for EPZM, this company’s Price to Tangible Book is 5.61 and its Price to Median PS Value is 1.02. Price to Peter Lynch Fair Value for EPZM is now 0.00.
Certain ratios provide helpful insights into how a stock is performing. The Quick Ratio for EPZM is sitting at 10.9, while its Current Ratio is 10.9. This stock’s PB Ratio is 5.62, its PS Ratio is 45.42. Similarly.